A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation
Active Date:
May 19, 2022
IRB Number:
APOLLO EA2192
Condition/Disease:
Pancreatic Cancer
Lead Researcher:
Hollis Walker, MD
Location:
Edward Cancer Center - Naperville
Purpose:
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Sponsor: ECOG-ACRIN
https://clinicaltrials.gov/ct2/show/NCT04858334
Eligibility:
Must have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease
No neuroendocrine tumors
Must have a mutation in BRCA1, BRCA2, or PALB2
Must not have had progression while receiving platinum-based therapy
No personal history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Time Commitment:
10 years
Status:
Accepting Participants
Current Trial Type:
Interventional
Phase:
II
Contact Name:
Meribeth Siatta, MSN
Phone:
331-221-2162
Fax:
331-221-3889
Alternate Phone:
630-646-6072